
Nicholaos C Bellos MD FIDSA FACP (He/Him)
Senior Medical Director Specialty Care Clinics
Join to view full profile
4211 Cedar Springs Ste200Dallas TxDallas, TX 75219
Dr. Bellos is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nicholaos Bellos is an infectious disease specialist based in Dallas, TX. He completed his fellowship in infectious disease at the University of Miami/Jackson Health System and his residency in internal medicine at Tulane University after graduating from Baylor College of Medicine in 1981. His professional expertise includes HIV/AIDS, travel and tropical medicine, osteomyelitis, nosocomial infections, and vaccines. Dr. Bellos has authored several publications on HIV treatment, with some highly cited works, such as his study on the efficacy of HIV treatments and drug safety. He has also been involved in clinical trials investigating new treatments for HIV and Hepatitis C co-infection.
Education & Training
University of Miami/Jackson Health SystemFellowship, Infectious Disease, 1987 - 1989
Tulane UniversityResidency, Internal Medicine, 1983 - 1987
Baylor College of MedicineClass of 1981
Memorial Healthcare System, Hollywood, FloridaResidency, Obstetrics and Gynecology
Certifications & Licensure
TX State Medical License 1982 - 2028
FL State Medical License 1987 - 2025
OK State Medical License 2014 - 2015
LA State Medical License 1984 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease
Clinical Trials
- BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
- Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients
Publications & Presentations
PubMed
- 68 citationsBrief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppre...François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel E. Gallant
Journal of Acquired Immune Deficiency Syndromes. 2017-06-01 - 24 citationsARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/LamivudineKathleen Squires, Benjamin Young, Edwin DeJesus, Nicholaos C. Bellos, Daniel Murphy
HIV Clinical Trials. 2012-09-01 - 5 citationsSimilar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Daniel J. Skiest, Calvin J. Cohen, Karam Mounzer, Zach Haigney, David Barker
HIV Clinical Trials. 2011-05-01
Professional Memberships
- Infectious Diseases Society of AmericaFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









